uniQure to Acquire Corlieve Therapeutics for $55M

Share this

uniQure to Acquire Corlieve Therapeutics for $55M


  • Corlieve to receive $55M upfront in cash and is eligible to receive $52.1M as development milestones for P-I/II and $191M for P-III development and the approvals of AMT-260 in the US and EU. the transaction is anticipated to be completed in Q3’21
  • The acquisition will foster Corlieve lead program- AMT-260- and allows to expands uniQure’s pipeline of innovative gene therapies to treat neurological disorders by using miRNA Silencing Technology
  • Corlieve has a license agreement with REGENXBIO that includes an exclusive license to AAV9 for the specific genetic target of AMT-260. REGENXBIO received equity in Corlieve and is eligible to receive milestone payments & royalties on net sales of AMT-260

Ref: Globe Newswire | Image: PR Newswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions